CA 72-4 Serum Marker–A New Tool in the Management of Carcinoma Patients

References

• Colcher D, Horan Hand P, Nuti M, Schlom J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA 1981; 78: 3199–3203
   PubMed Web of Science ®Google Scholar
• Thor A, Ohuchi N, Szpak C A, et al. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res 1986; 46: 3118–3124
   PubMed Web of Science ®Google Scholar
• Johnson V G, Schlom J, Paterson A, et al. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res 1986; 46: 850–857
   PubMed Web of Science ®Google Scholar
• Thor A, Viglione M J, Muraro O, et al. Monoclonal antibody B72.3 reactivity with human endometrium: A study of normal and malignant tissue. Int J Gynecol Pathol 1987; 6: 235–247
   PubMed Web of Science ®Google Scholar
• Xu M, Real F X, Welt S, et al. Expression of TAG-72 in normal colon, transitional mucosa, and colon cancer. Int J Cancer 1989; 44: 985–989
   PubMed Web of Science ®Google Scholar
• Muraro R, Kuroki D, Wunderlich D, et al. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor associated glycoprotein 72 antigen. Cancer Res 1988; 48: 4588–4596
   PubMed Web of Science ®Google Scholar
• Gero E J, Colcher D, Ferroni P, et al. The CA 72–4 radioimmunoassay for the detection of the TAG-72 carcinoma associated antigen in serum of patients. J Clin Lab Anal 1989; 3: 360–369
   PubMed Web of Science ®Google Scholar
• Ferroni P, Szpak C, Greiner J W, et al. CA 72–4 radioimmunoassay in the diagnosis of malignant effusions. Comparison of various tumor markers. Int J Cancer 1990; 46: 445–451
   PubMed Web of Science ®Google Scholar
• Ohuchi N, Takahashi K, Matoba N, et al. Comparison of serum assay for TAG-72, CA 19–9, and CEA in gastrointestinal carcinoma patients. Jpn J Clin Oncol 1989; 19: 242–248
   PubMed Web of Science ®Google Scholar
• Ohuchi N, Gero E, Mori S, et al. Clinical evaluation of CA 72–4 immunoradiometric assay for serum TAG-72 antigen in patients with carcinoma. J Tumor Marker Oncol 1990; 5: 1–10
   Google Scholar
• Thor A, Gorstein F, Ohuchi N, et al. Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3. J Natl Cancer Inst 1986; 76(6)995–1006
   PubMed Web of Science ®Google Scholar
• Bast R C, Klug T L, St. John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309: 883–887
   PubMed Web of Science ®Google Scholar
• Jacobs J, Bast R C. The CA 125 tumor-associated antigen: A review of the literature. Hum Reprod 1989; 4(1)1–12
   PubMed Web of Science ®Google Scholar
• Fuzakawa I, Inaba N, Ota Y, et al. Serum levels of six tumor markers in patients with benign and malignant gynecological disease. Arch Gynecol Obstet 1988; 243: 61–68
   PubMed Web of Science ®Google Scholar
• Zurawski V R, Knapp R C, Einhorn N, et al. An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. Gynecol Oncol 1988; 30: 7–14
   PubMed Web of Science ®Google Scholar
• Niloff J M, Bast R C, Schaetzl E M, Knapp R C. Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. Am J Obstet Gynecol 1985; 151: 981–986
   PubMed Web of Science ®Google Scholar
• Brioschi P A, Bischof P, Rapin C, et al. Longitudinal study of carcinoembryonic antigen and cancer antigen CA 125 in ovarian cancer. Gynecol Oncol 1985; 21(l)l–6
   Google Scholar
• Atack D B, Nisker J A, Allen H H, et al. CA 125 surveillance and second-look laparotomy in ovarian carcinoma. Am J Obstet Gynecol 1986; 154: 287–289
   PubMed Web of Science ®Google Scholar
• Schwart P E, Chambers S K, Chambers J T, et al. Circulating tumor markers in the monitoring of gynecologic malignancies. Cancer 1987; 60: 353–361
   PubMed Web of Science ®Google Scholar
• Soper J T, Hunter V J, Daly L, et al. Preoperative serum tumor-associated antigen levels in women with pelvic masses. Obstet Gynecol 1990; 75: 249–254
   PubMed Web of Science ®Google Scholar
• Bast R C, Jr, Knauf S, Epenetos A, et al. Coordinate evaluation of serum markers in ovarian cancer but not in benign disease. Cancer 1991; 68: 1758–1763
   PubMed Web of Science ®Google Scholar
• Einhorn N, Knapp R C, Bast R C, Jr, Zurawski V R, Jr. CA 125 used in conjunction with CA 125 and TAG-72 assay for the discrimination between malignant and non-malignant diseases of the ovary. Acta Oncol 1989; 28: 655–657
   PubMed Web of Science ®Google Scholar
• Guadagni F, Marth C, Zeimet A G, et al. Evaluation of tumor-associated glycoprotein-72 and CA 125 serum markers in patients with gynecologic diseases. Am J Obstet Gynecol 1994; 171: 1183–1191, 1993
   PubMed Web of Science ®Google Scholar
• Guadagni F, Roselli M, Amato T, et al. Tumor-associated glycoprotein-72 (TAG-72) serum levels complement carcinoembryonic antigen levels in monitoring patients with gastrointestinal carcinoma: A longitudinal study. Cancer 1991; 68: 2443–2450
   PubMed Web of Science ®Google Scholar
• Guadagni F, Roselli M, Cosimelli M, et al. TAG-72 (CA 72–4 assay) as a complementary serum tumor antigen to CEA in monitoring patients with colorectal cancer. Cancer 1993; 72: 2098–2106
   PubMed Web of Science ®Google Scholar
• Guadagni F, Roselli M, Amato T, et al. The CA 72–4 assay as a serum marker in the management of gastric carcinoma. Cancer Res 1992; 52: 1222–1227
   PubMed Web of Science ®Google Scholar
• Guadagni F, Roselli M, Cosimelli M, et al. Correlation between positive CA 72–4 serum levels and lymph node involvement in patients with gastric carcinoma. Anticancer Res 1993; 13: 2409–2414
   PubMed Web of Science ®Google Scholar
• Wanebo H J, Rao B, Pinsky C M, et al. Preoperative carcinoembryonic antigen levels as a prognostic indicator of colorectal cancer. N Engl J Med 1978; 299: 448–451
   PubMed Web of Science ®Google Scholar
• Goldenberg D M, Neville A M, Cortes A C, et al. Carcinoembryonic antigen: Its role as a marker in the management of cancer: A National Institutes of Health Consensus Development Conference. Ann Intern Med 1987; 94: 407–409
   Google Scholar
• Sikorska H, Shuster J, Gold P. Clinical applications of carcinoembryonic antigen. Cancer Detect Prev 1988; 12: 321–355
   PubMedGoogle Scholar
• Mach J P, Jaeger P, Bertholet M M. Detection of recurrence of large-bowel carcinoma by radioimmunoassay of circulating carcinoembryonic antigen (CEA). Lancet 1974; 7: 535–540
   Google Scholar
• Tomoda H, Furusawa M. The usefulness and limitations of CEA assay in the management colorectal cancer. Jpn J Surg 1981; 11: 33–38
   PubMedGoogle Scholar
• Lunde O CH, Havig O. Clinical significance of carcinoembryonic antigen in patients with adenocarcinoma in colon and rectum. Acta ChirScand 1982; 42: 148–193
   Google Scholar
• Cullen K J, Stevens D P, Frost M A, et al. Carcinoembryonic antigen (CEA), smoking and cancer in a longitudinal population study. Aust NZ J Med 1976; 6: 279–283
   PubMedGoogle Scholar
• Bullen A W, Losowsky M S, Carter S, et al. Diagnostic usefulness of plasma carcinoembryonic antigen levels in acute and chronic liver disease. Gastroenterology 1977; 73(4)673–678
   PubMed Web of Science ®Google Scholar
• Lowenstein M S, Zamcheck N. Carcinoembryonic antigen and the liver. Gastroenterology 1977; 72: 161–166
   PubMed Web of Science ®Google Scholar
• Guadagni F, Roselli M, Amato T, et al. Clinical evaluation of serum tumor-associated glycoprotein-72 as a novel tumor marker for colorectal cancer patients. J Surg Oncol 1991; 2: 16–20
   Google Scholar
• Moertel C G, O'Fallon J R, Go V LW, et al. The preoperative carcinoembryonic antigen test in the diagnosis, staging and prognosis of colorectal cancer. Cancer 1986; 58: 603–610
   PubMed Web of Science ®Google Scholar
• Goldenberg D M, Neville A M, Carter A C, et al. Carcinoembryonic antigen: Its role as a marker in the management of cancer: A National Institutes of Health Consensus Development Conference. Cancer Res 1981; 41: 2017–2018
   PubMed Web of Science ®Google Scholar
• Herlyn M, Sears H F, Steplewski Z, Koprowski H. Monoclonal antibody detection of a circulating tumor-associated anti- gen. I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma. J Clin Immunol 1982; 2: 135–140
   PubMed Web of Science ®Google Scholar
• Del Villano B C, Brennan S, Brock P, et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19–9. Clin Chem 1983; 29: 549–552
   PubMed Web of Science ®Google Scholar
• Ritts R E, Jr, Del Villano B C, Go V L, et al. Initial clinical evaluation of an immunoradiometric assay for CA 19–9 using the NCI serum bank. Int J Cancer 1984; 33: 339–345
   PubMed Web of Science ®Google Scholar
• Koga T, Kano T, Souda K, et al. The clinical usefulness of preoperative CEA determination in gastric cancer. Jpn J Surg 1987; 17(5)342–347
   PubMedGoogle Scholar
• Lowenstein M S, Zamcheck N. Carcinoembryonic antigen levels in benign gastrointestinal disease states. Cancer 1978; 42: 1412–1418
   PubMed Web of Science ®Google Scholar
• Sipponen P, Lindgren J. Sialylated Lewis determinant CA 19–9 in benign and malignant gastric tissue. Acta Pathol Microbiol Immunol Scand Sect A 1986; 94: 305–311
   PubMedGoogle Scholar
• Staab H J, Hournung A, Anderer F A, Kiieninger G. Clinical significance of the circulating tumor-associated antigen CA 19–9 in cancers of the digestive tract. Dtsch Med Wochenschr 1984; 109: 1141–1146
   PubMed Web of Science ®Google Scholar
• Byrne D J, Browning M CK, Cuschieri A. CA 72–4: A new tumour marker for gastric cancer. Br J Surg 1990; 77: 1010–1013
   PubMed Web of Science ®Google Scholar